Navigation Links
PharmTech in Medical News

Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia

SEOUL, South Korea, Oct. 15 /PRNewswire/ -- Dong-A PharmTech Co. Ltd announced today the signing of a five-year US$50 Million contract with Otechestvennye Lekarstva OJSC, to market in Russia Dong-A's erectile dysfunction drug which is currently sold in Korea under the brand name of Zydena. Un...

Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance

...se of $11.7 million, or 96.0%, compared with the prior year quarter. Included in the quarter ended March 31, 2009 was a $9.0 million payment to Dong-A pharmtech Co. Ltd. upon the achievement of a developmental milestone under our existing agreement for udenafil, an orally administered product for the treatment...

Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008

...th the prior year quarter. Included in R&D in the quarter ended December 31, 2008 was a $2.0 million expense to acquire certain rights from Dong-A pharmtech Co. Ltd. to develop and market its orally-administered udenafil product for the treatment of erectile dysfunction ("ED"). Excluding this $2.0 million ...

Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment

...ILTON, Bermuda, Jan. 6 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX ) today announced that it has signed an agreement with Dong-A pharmtech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatm...
PharmTech in Medical Technology

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that its European licensee, Dr. Falk Pharma, has initiated a 200 patient, phase 2 proof of concept clinical study to investigate the use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for por...

Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil, Its New Long Acting Drug For Erectile Dysfunction

All Endpoints Met - Up to 88% Efficacy SEOUL, Korea, March 28, 2007 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that it has completed a 340 patient phase 2b "at-home" clinical study for udenafil, its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor ...
Other Tags
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Becker's Hospital Review has published the ... and Health Systems With Great Orthopedic Programs." , ... list have orthopedic surgery departments, programs or dedicated ... sources. Exceptional orthopedic departments include physicians who provide ... treat professional athletes. , This is the fifth ...
(Date:9/23/2014)... under the curve of oxygen desaturation" (AUC Desat ) ... oxygen levels during procedures using sedation, according to a ... The AUC Desat provides information not only whether ... depth, duration, and rate of episodes of oxygen desaturation. ... University of Cincinnati and colleagues reports on the development ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Kenall ... has expanded its MedMaster™ M4 product line with ... extends the M4 product line – currently available ... options – providing more flexibility when designing lighting ... MedMaster M4 Series include:, •Three sizes ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
(Date:9/22/2014)... the country selected by the National Institutes of ... a $2 million grant designed to expose ... graduate trainees to career opportunities that go beyond ... , The award funds development of the Rutgers ... It includes courses, seminars, shadowing, mentoring and networking ...
(Date:9/22/2014)... manufacturing (AM), or 3D printing, has rapidly advanced ... components strong enough for structural applications. However, developing ... well as quality standards to test the manufactured ... Engineers at the University of Pittsburgh,s Swanson School ... and simulation (M&S) technology and new qualification standards ...
(Date:9/22/2014)... you,re overweight, you may be at greater risk ... disease and cancer, according to a new study ... psychological stress can trigger biological responses similar to ... While normal inflammation is an important part of ... to chronic and life-threatening diseases. , In ...
Breaking Biology News(10 mins):Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3Obesity and stress pack a double hit for health 2
Other Contents